MedTrace Logo

Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)

NCT05798533 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2023-07-10

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety of Neo-T in combination with anti-PD1 in patients with solid tumors.

The secondary objective of this study is to evaluate preliminarily the effect of Neo-T in combination with anti-PD1 in patients with solid tumors.

Conditions

Interventions

BIOLOGICAL

Neo-T

Patients will receive Neo-T iv on day 0. Three times of cell infusion with an interval of 7 days constitute a cycle,maximum four cycles of treatment for patients.

COMBINATION_PRODUCT

Toripalimab

3mg/kg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 2 weeks. Toripalimab is recommended for patients with Melanoma.

COMBINATION_PRODUCT

Tislelizumab

200mg iv; Within 7 days after the first PBMC collection (day-38±3), the first dose was administered, and thereafter every 3 weeks. Tislelizumab is recommended for patients with NSCLC or other tumor types.

Sponsors & Collaborators

  • Fudan University

    collaborator OTHER

  • Shanghai 10th People's Hospital

    collaborator OTHER

  • BGI, China

    lead OTHER

Principal Investigators

  • Jian Zhang, Doctor · Fudan University

  • Yong Chen, Doctor · Fudan University

  • Qing Xu, Doctor · Shanghai 10th People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2023-09-30
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05798533 on ClinicalTrials.gov